Solid nanoparticles for oral antimicrobial drug delivery: a review

Raza, Aun; Sime, Fekade Bruck; Cabot, Peter J.; Maqbool, Faheem; Roberts, Jason A.; Falconer, James R.

doi:10.1016/j.drudis.2019.01.004

Cited by 96 publications

(55 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, commercially available AmB lipid formulations for the treatment of invasive fungal infections are expensive and require parenteral administration, increasing length of hospital stay and healthcare costs. Therefore, the development of an orally available AmB formulation able to decrease the systemic toxicity of the drug, avoid infusion-related adverse events, improve patient compliance, and reduce the costs associated with commercial AmB formulations for intravenous administration is an urgent requirement [41,[158][159][160]. Lipid-based systems for AmB delivery which mainly developed over the last five years are summarized in Table 2 and will be further discussed in the next sections.…”

Section: Investigational Lipid-based Systems For Amphotericin B Deliverymentioning

confidence: 99%

“…The improved bioavailability observed with oral delivery of SLNs could be related to an increase of residence time within the gut due to the interactions of lipids on the surface of NPs with the epithelial membranes [160]. Gastric and intestinal enzymes are prone to degrade lipid-based delivery systems and absorption can be enhanced in the course of the digestion of triglycerides from SLNs by pancreatic lipase [239,240].…”

Section: Solid Lipid Nanoparticles and Nanostructured Lipid Carriersmentioning

confidence: 99%

See 1 more Smart Citation

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

Amphotericin B (AmB), a broad-spectrum polyene antibiotic in the clinic for more than fifty years, remains the gold standard in the treatment of life-threatening invasive fungal infections and visceral leishmaniasis. Due to its poor water solubility and membrane permeability, AmB is conventionally formulated with deoxycholate as a micellar suspension for intravenous administration, but severe infusion-related side effects and nephrotoxicity hamper its therapeutic potential. Lipid-based formulations, such as liposomal AmB, have been developed which significantly reduce the toxic side effects of the drug. However, their high cost and the need for parenteral administration limit their widespread use. Therefore, delivery systems that can retain or even enhance antimicrobial efficacy while simultaneously reducing AmB adverse events are an active area of research. Among those, lipid systems have been extensively investigated due to the high affinity of AmB for binding lipids. The development of a safe and cost-effective oral formulation able to improve drug accessibility would be a major breakthrough, and several lipid systems for the oral delivery of AmB are currently under development. This review summarizes recent advances in lipid-based systems for targeted delivery of AmB focusing on non-parenteral nanoparticulate formulations mainly investigated over the last five years and highlighting those that are currently in clinical trials.

show abstract

Section: Investigational Lipid-based Systems For Amphotericin B Deliverymentioning

confidence: 99%

Section: Solid Lipid Nanoparticles and Nanostructured Lipid Carriersmentioning

confidence: 99%

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

2020

View full text Add to dashboard Cite

show abstract

“…Several NPs such as Si, SiO 2 [15,87], MgO [88], CaO [89], and Al 2 O 3 [90] have shown significant antibacterial activity. High surface area in nanoscale, low cost, and nanocomposite formation with NPs make SiO 2 an available option against MDR bacteria, especially for potential clinical nanomaterials to treat oral biofilms [91]. Yamamoto et al [92] showed that the generation of superoxide on their surface was the major reaction mechanism of antibacterial action by CaO and MgO.…”

Section: New Antibacterial Nanomaterials On the Block With New Strmentioning

confidence: 99%

Nanomaterials as Delivery Vehicles and Components of New Strategies to Combat Bacterial Infections: Advantages and Limitations

Naskar

Kim

2019

Microorganisms

View full text Add to dashboard Cite

Life-threatening bacterial infections have been well-controlled by antibiotic therapies and this approach has greatly improved the health and lifespan of human beings. However, the rapid and worldwide emergence of multidrug resistant (MDR) bacteria has forced researchers to find alternative treatments for MDR infections as MDR bacteria can sometimes resist all the present day antibiotic therapies. In this respect, nanomaterials have emerged as innovative antimicrobial agents that can be a potential solution against MDR bacteria. The present review discusses the advantages of nanomaterials as potential medical means and carriers of antibacterial activity, the types of nanomaterials used for antibacterial agents, strategies to tackle toxicity of nanomaterials for clinical applications, and limitations which need extensive studies to overcome. The current progress of using different types of nanomaterials, including new emerging strategies for the single purpose of combating bacterial infections, is also discussed in detail.

show abstract

“…Nanoparticles have been widely investigated as drug delivery systems to increase the therapeutic efficacy of drugs [12][13][14][15][16] and reduce their side effects [17,18]. Nanoparticles have a high surface area to volume ratio; therefore, they could encapsulate drugs in high concentrations and increase drug delivery to cancerous cells [19].…”

Section: Introductionmentioning

confidence: 99%

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

et al. 2020

Self Cite

View full text Add to dashboard Cite

This study aimed to evaluate the therapeutic efficacy of the cisplatin encapsulated into polybutylcyanoacrylate (PBCA) nanoparticles for the treatment of kidney cancer. The nanoformulation was successfully developed using the miniemulsion polymerization method and characterized in terms of size, size distribution, drug loading and encapsulation efficiencies, drug release behavior, in vitro cytotoxicity effects, in vivo toxicity, and therapeutic effects. Cisplatin-loaded PBCA nanoparticles were confirmed to be in nanoscale with the drug entrapment efficiency of 23% and controlled drug release profile, in which only 9% of the loaded drug was released after 48 h. The nanoparticles caused an increase in the cytotoxicity effects of cisplatin against renal cell adenocarcinoma cells (ACHN) (2.3-fold) and considerably decreased blood urea nitrogen and creatinine concentrations when compared to the standard cisplatin (1.6-fold and 1.5-fold, respectively). The nanoformulation also caused an increase in the therapeutic effects of cisplatin by 1.8-fold, in which a reduction in the mean tumor size was seen (3.5 mm vs. 6.5 mm) when compared to the standard cisplatin receiver rats. Overall, cisplatin-loaded PBCA nanoparticles can be considered as a promising drug candidate for the treatment of kidney cancer due to its potency to reduce the side effects of cisplatin and its toxicity and therapeutic effects on cancer-bearing Wistar rats.

show abstract

Solid nanoparticles for oral antimicrobial drug delivery: a review

Cited by 96 publications

References 79 publications

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

Lipid Systems for the Delivery of Amphotericin B in Antifungal Therapy

Nanomaterials as Delivery Vehicles and Components of New Strategies to Combat Bacterial Infections: Advantages and Limitations

Preparation, Characterization, and Evaluation of Cisplatin-Loaded Polybutylcyanoacrylate Nanoparticles with Improved In Vitro and In Vivo Anticancer Activities

Contact Info

Product

Resources

About